TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 14 days as one course. When it corresponds to administration change criteria, TS-1 was administered orally at 40
Sponsors
Department of surgery, Kansai Medical University.
Conditions
Metastatic or locally advanced pancreatic cancer
Unknown Phase
A feasibility study of TS-1 schedule modification in patients with metastatic and locally advanced pancreatic cancer
RecruitingJPRN-UMIN000007451
Start: 2012-01-01Target: 30Updated: 2026-06-29
A feasibility study of TS-1 schedule modification in elderly patients with metastatic and locally advanced pancreatic cancer
RecruitingJPRN-UMIN000007452
Start: 2012-01-01Target: 30Updated: 2026-06-29